Guardant Health

Liquid biopsy detects fragments of tumor DNA that tumors shed into the bloodstream, called circulating tumor DNA or ctDNA. Guardant's platform sequences those fragments from a standard blood draw — 10 milliliters of blood — and analyzes them for genomic alterations that drive cancer growth. The flagship Guardant360 test covers over 70 genes, reporting mutations, fusions, and amplifications that help oncologists select targeted therapies or match patients to clinical trials.

Guardant sells exclusively through healthcare providers and biopharma partners. No direct-to-consumer channel exists as of the current period. Tests must be ordered by a licensed physician, and the blood draw is performed in a clinical setting. The company receives orders from community oncologists, academic medical centers, and contract research organizations running cancer-drug trials.

Revenue splits into two segments: clinical testing and biopharma services. Clinical revenue comes from oncologists ordering Guardant360 and Guardant Reveal tests for individual patients, reimbursed by Medicare, commercial insurers, and hospital systems. Biopharma revenue comes from pharmaceutical companies that contract Guardant to sequence patient samples in clinical trials, using the company's platform as a companion diagnostic-development tool. In 2023, biopharma contributed a meaningful minority of total revenue.

Guardant360 CDx received FDA approval as a companion diagnostic in 2020, meaning it can be used to identify patients eligible for specific targeted therapies. The Shield screening test received FDA approval in July 2024 for colorectal cancer screening. Most other Guardant tests run as laboratory-developed tests under CLIA regulations, giving the company regulatory flexibility but less pricing protection. FDA approval matters because it unlocks Medicare coverage and distinguishes the product from competitors without the same clearance.

The primary competitors are Exact Sciences, which sells the Cologuard stool-DNA test and has entered the liquid-biopsy market through the acquisition of Thrive Earlier Detection, and Foundation Medicine, a Roche subsidiary that dominates tissue-based comprehensive genomic profiling. NeoGenomics also competes in oncology testing. In the screening market specifically, Exact Sciences' Cologuard and Quest Diagnostics' various offerings represent the main competitive threats.

Helmy Eltoukhy and AmirAli Talasaz serve as Co-CEOs, with Talasaz also holding the role of Chairman. Both were founding team members and have run the company jointly since inception. The arrangement is unusual for a publicly traded company of Guardant's scale. Day-to-day divisions are not publicly detailed, but Talasaz has historically led scientific and clinical development while Eltoukhy has focused on commercial operations and administrative functions.

Medicare covers Guardant360 for advanced solid tumors through multiple local coverage determinations, and the addition of FDA approval for Guardant360 CDx strengthened that coverage. Medicare also covers Guardant Reveal for colorectal cancer recurrence monitoring. With the July 2024 FDA approval of Shield, the company now seeks Medicare coverage for its colorectal cancer screening test, which would represent a significant reimbursement expansion if granted.